The Amylin Mystery And Bydureon Sales - Forbes

Links shared publicly online about this topic.

  • 0
    total visits

The Amylin Mystery And Bydureon Sales - Forbes

forbes.com

As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and its rejection of a bid by Bristol-Myers Squibb – did the big drugmaker really make a bid? if so, when? and why did Amylin say no? – a key issue has been the value of the Bydureon diabetes drug.

View full resource at forbes.com

Tags:

  • Share

Most Recently Shared on April 17, 2012 at 9:04 pm By:

blogaceutics blogaceutics

The Amylin Mystery And Bydureon Sales - Forbes http://t.co/xFXHTY4O

4 days ago...

Also Shared By:

Scott Strumello Scott Strumello

Advertisement